Düsseldorf, Germany, December 12, 2017 -- Syndivia receives a winning award at the European Venture Contest Final as one of the top 20 companies, selected from over 1250+ applications and 600+ pitches held throughout the Tech Tour 2017. Official press-release: view online here
PARIS, France, February 2, 2017 -- Syndivia wins the France Tech Transfer Invest Award during a Tech Tour event that took place in Paris on 1-2 February 2017. The event is a collaboration between the SATT, Tech Tour, Bpifrance and its EuroQuity platform and aims to efficiently and effectively support French tech companies to meet and engage with international investors and corporate partners.
For more information on the event visit: http://techtour.com/events/view.aspx?events_pages_id=7749
NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Syndivia SAS, a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).
Full press release available at: http://globenewswire.com/news-release/2016/09/06/869521/10164974/en/OGD2-Pharma-and-Syndivia-launch-collaboration-to-develop-an-ADC-targeting-the-O-acetyl-GD2-cancer-antigen.html
The European Commission has named Syndivia as one of the new Phase 1 beneficiaries of the European Union's SME Instrument. SME Instrument is a highly competitive grant that supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. The SME Instrument Phase 1 grant is aimed to fund the feasibility assessment of Syndivia's next-generation targeted cancer therapies.
Syndivia is looking for a highly motivated candidate for a PhD project on characterisation of antibody-drug conjugates by mass spectrometry.
The responsibilities of the candidate will include:
- Development of high-throughput analytical methods for determination of drug-to antibody ratio (DAR)
- Identification of conjugation sites in site-specific and classical antibody-drug conjugates
- Collaborating with outside groups on project-related studies.
An ideal candidate will have knowledge and experience in:
- Native mass spectrometry
Please, send your CV, a motivation letter and names of two referees to email@example.com
Syndivia has signed a distribution agreement with Sigma-Aldrich. Following this agreement, Syndivia’s proprietary bioconjugation reagents are now available in the catalog of Sigma-Aldrich. For the complete list of products visit: http://www.sigmaaldrich.com/catalog/search?term=apn
“It is our priority to provide the research community with the cutting-edge tools for bioconjugation. Commercialization of APN reagents is an important step for advancing therapeutic and diagnostic applications of bioconjugates” – commented Oleksandr Koniev, Syndivia’s CEO.
May 23-24, Syndivia's CEO will be giving a talk at the SMi's annual ADC Summit in London.
The topics covered in the talk will include:
• New ADC linkers with increased serum stability
• Next-generation DM1- and MMAE-based payloads
• Expanding the scope of ADC targets by fine-tuning the drug release properties
For more information, visit the website of the conference:
Syndivia introduces a first-in-class reagent for kinetically resolved thiol-to-thiol conjugation in its recent publication in Bioconjugate Chemistry. The MAPN reagent allows for the preparation of stable Antibody-Drug Conjugates through conjugation of thiol-containing drugs to the cysteine residues of the antibody.
The publication can be downloaded on the ACS website: http://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.5b00440